B&C CRYOINNOV : revenue, balance sheet and financial ratios

Revenue 2023 119 k€ -12 % vs 2022
EBITDA 2023 -234 k€
Net income 2023 -279 k€

B&C CRYOINNOV is a French company founded 11 years ago, specialized in the sector Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé. Based in MELESSE (35520), this company of category PME shows in 2023 a revenue of 119 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

At a glance (2023) : revenue 119 k€, EBITDA -234 k€ (-196.0 % of revenue), net income -279 k€. Balance sheet : equity -2,6 M€, financial debt 2,9 M€, cash 41 k€.

Data updated on 2026-09-19

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

About this data : outdated accounts

Le dernier exercice comptable publié pour cette entreprise remonte à 2023. Les données ci-dessous peuvent ne plus refléter sa situation actuelle.

Synthèse

Santé financière : Fragile

Signal structurel : capitaux propres négatifs ; exploitation déficitaire (EBE négatif).

In summary, B&C CRYOINNOV is currently loss-making, which weighs on its accounts. Its financial structure is severely weakened: equity is negative.

Financial history - B&C CRYOINNOV (SIREN 805350329) · amounts in thousands of euros (€k)
Indicator 2023 2022
Revenue 119 136
Net income -279 -279
EBITDA -234 -244
Gross margin 63 82
Operating income -233 -238
Net margin -233,5 % -204,9 %
Equity -2 643 -2 364
Financial debt 2 881 2 663
Cash 41 61
Tax returns Download accounts (CSV / Excel)

Revenue and income statement

In 2023, B&C CRYOINNOV achieves revenue of 119 k€. Significant drop of -12% vs 2022. After deducting consumption (57 k€), gross margin stands at 63 k€, i.e. a rate of 53%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -234 k€, representing -196.0% of revenue. Le chiffre d'affaires recule de 12 % et l'EBE de +4 % : les charges n'ont pas baissé au même rythme que l'activité, ce qui réduit la marge de 17,0 points. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -279 k€ (-233.5% of revenue), which will impact equity.

Revenue (2023) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

119 486 €

Gross margin (2023) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

62 974 €

EBITDA (2023) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-234 202 €

EBIT (2023) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-232 903 €

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-279 037 €

EBITDA margin (2023) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-196,0 %

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

Warning: the company shows negative equity (accumulated losses exceed its capital). This is a major financial weakness which makes debt and autonomy ratios non-meaningful.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

Non significatif

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

Non significatif

Cash flow / Revenue (2023) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-234,6 %

Repayment capacity (2023) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-10,3 ans

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

1,3 %

Solvency indicators evolution
B&C CRYOINNOV

Sector positioning

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 7.65. Compared with its sector, this ratio places the company among the best positioned (sector median: 2.1).

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

7,65

Liquidity indicators evolution
B&C CRYOINNOV

Sector positioning

Liquidity ratio
7,65 2023
Q1: 1,45
Med: 2,12
Q3: 3,37
Excellent 6 → 7,7 depuis 2022

In 2023, the liquidity ratio of B&C CRYOINNOV (7,65) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 65 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 43 days. The company must finance 22 days of gap between collections and payments. Inventory turnover is 563 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 599 days of revenue, i.e. 199 k€ to permanently finance. Between 2022 and 2023, WCR improved by 98 days of revenue, freeing up cash.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

198 824 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

65 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

43 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

563 j

WCR in days of revenue (2023) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

599 j

WCR and payment terms evolution
B&C CRYOINNOV

Positioning of B&C CRYOINNOV in its sector

Comparison with sector Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé

Similar companies (Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé)

Compare B&C CRYOINNOV with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé

Top companies in Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé

Largest companies by revenue in the sector Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé:

Top companies in Ille-et-Vilaine

Largest companies by revenue in the department Ille-et-Vilaine:

Voir le classement complet du département Ille-et-Vilaine

Frequently asked questions about B&C CRYOINNOV

What is the revenue of B&C CRYOINNOV ?

The revenue of B&C CRYOINNOV in 2023 is 119 k€.

Is B&C CRYOINNOV profitable?

B&C CRYOINNOV recorded a net loss in 2023.

Where is the headquarters of B&C CRYOINNOV ?

The headquarters of B&C CRYOINNOV is located in MELESSE (35520), in the department Ille-et-Vilaine.

Where to find the tax return of B&C CRYOINNOV ?

The tax return of B&C CRYOINNOV is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does B&C CRYOINNOV operate?

B&C CRYOINNOV operates in the sector Commerce de détail d'articles médicaux et orthopédiques en magasin spécialisé (NAF code 47.74Z). See the 'Sector positioning' section above to compare the company with its competitors.